One platform. Multiple programs. Every needle-accessible tumor.
A single Symphony™ HD-Ad architecture — 1 drug substance, 1 drug product, 1 injection — re-pointed by tumor-specific promoter and payload swap across indications. FIG-001 leads in prostate cancer; FIG-002–004 target B7-H3, HER2+, and EGFR overexpressing solid tumors.
Development stage as of Q3 2026. All programs share the Symphony™ HD-Ad platform; indication expansion is achieved by swapping tumor-specific promoters and payload cassettes.
Two prostate entry points in parallel — then broad solid-tumor expansion.
A $100B+ solid-tumor immuno-oncology TAM. FIG leads with prostate, following peer clinical validation, and expands the same architecture across every solid tumor a needle can reach.
Metastatic castration-resistant prostate cancer
Where the current standard of care fails. mCRPC is essentially incurable — the endpoint of a 1–2 year castration-driven resistance cascade. Peer clinical validation (Syncromune) confirms that multimodal intratumoral therapy can generate responses here; FIG delivers the same mechanisms from a single injection.
High-risk localized prostate cancer — neoadjuvant
~25% of prostate cancer diagnoses are high-risk localized. Even after definitive therapy, ~50% recur through micrometastatic disease. A single neoadjuvant intratumoral injection before surgery or radiation aims to train systemic immunity to find and clear those cells — before castration therapy is ever needed.
Any needle-accessible solid tumor
Cold tumors — triple-negative breast, ICI-resistant melanoma, head & neck, lung, bladder — share the same suppression network. For unresectable cancers like glioblastoma, a single image-guided injection acts as an in-situ microsurgeon: recruit, prime, and lyse without cutting.
A disease that fails every immunotherapy tried on it.
Prostate cancer is one of the most immune-cold tumors in oncology. Single agents don't work. Tolerated combinations don't either. Multimodal intratumoral therapy is the answer — and FIG delivers it from a single injection.
Train the immune system to find and clear micrometastatic cells before castration is ever needed — a single neoadjuvant intratumoral injection for high-risk localized disease. And for patients already at mCRPC, deliver every mechanism Syncromune validates in one drug substance, one drug product, one injection — without the device, the repeated procedures, or the four-biologic manufacturing burden.
From preclinical to first Phase 3 readout.
A capital-efficient path from lead nomination to clinical validation.
- Robust in vitro and in vivo validation
- Lead optimization
- FDA INTERACT meeting
- GMP manufacturing
- GLP Tox and biodistribution
- IND-enabling studies
- IND filing
- Phase 1 initiation
- Phase 2 initiation
- Phase 3 initiation